Influenza A Virus, Split Virion
drugOn this page
Also known as ArepanrixHumenzaInfluenza a virussplit virionsplit virion component of idflusplit virion component of intanzaPandemrixPrepandrixPumarix
Summary
Influenza A Virus, Split Virion (CHEMBL6068363) is an approved vaccine component; indicated across 2 conditions including influenza.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- Indications: 2 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068363 |
| Name | Influenza A Virus, Split Virion |
| Type | Vaccine component |
| Max phase | 4 |
Also known as: Arepanrix, Humenza, Influenza a virus, split virion, split virion component of idflu, split virion component of intanza, Pandemrix, Prepandrix, Pumarix, INFLUENZA A VIRUS, SPLIT VIRION
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| influenza | 4 | MONDO:0005812 | EFO:0007328 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01000831 | PHASE4 | COMPLETED | Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children |
| NCT01001026 | PHASE4 | COMPLETED | Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults |
| NCT01002040 | PHASE4 | COMPLETED | Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: influenza